Jan 29 (Reuters) - Insulin delivery device maker Beta Bionics said on Wednesday it raised $204 million in its initial public offering $(IPO.UK)$ at a valuation of about $700 million.

The U.S.-based company said it priced its IPO at $17 per share, the upper-end of its forecasted range of $16 to $17 per share.

The size of the offering was raised to 12 million shares from 10 million shares, the company said.

Beta bucks the recent trend where major IPO candidates such as LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O had to lower their valuation targets.

Beta's shares will start trading on the Nasdaq under the symbol "BBNX" on Thursday.

BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street are the underwriters for the offering.

(Reporting by Kritika Singh in Bengaluru; Editing by Savio D'Souza)

((Kritika.Singh@thomsonreuters.com;))